Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal...

cafead

Administrator
Staff member
  • cafead   Jan 30, 2020 at 09:23: PM
via Branded drugmakers often take creative strategies to protect their meds from generic competition. In United Therapeutics' case, the lever for shielding Remodulin was an exclusive deal with a drug-pump maker, or so Novartis' Sandoz contended. But a judge didn't buy that argument.

article source
 

<